甲硝唑
细菌性阴道病
阴道菌群
乳酸菌
不利影响
医学
内科学
抗生素
胃肠病学
微生物学
生物
妇科
细菌
遗传学
作者
Shuai Lou,Hongqing Lv,Lin Zhang
标识
DOI:10.4314/tjpr.v23i5.11
摘要
Purpose: To evaluate the effectiveness of metronidazole in combination with Lactobacillus live capsules for the treatment of bacterial vaginosis (BV). Methods: A retrospective study of 100 BV patients was conducted between June 2020 and February 2022 at Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China. Patients were assigned to control (48 patients received metronidazole only) and study groups (52 patients received metronidazole and Lactobacillus live capsules). Short-term efficacy, changes in vaginal flora distribution, recurrence rates, and occurrence of adverse effects were investigated. Results: The study group showed significantly higher overall efficacy compared to control group (p < 0.05). After treatment, vaginal flora analysis revealed a more balanced microbiota in the study group, indicating a positive effect of combined therapy. However, recurrence rates at one and three months after treatment did not significantly differ between the two groups (p > 0.05). Both treatment regimens were generally well-tolerated, with only a single report of mild adverse reactions in the study group. Conclusions: The combined therapy of metronidazole and Lactobacillus live capsules enhances shortterm therapeutic effectiveness and promotes a healthier vaginal microbiota. Although, the combined therapy does not significantly impact recurrence rates, it demonstrates a favorable safety profile. The lack of attention to non-bacterial constituents of the vaginal flora and potential long-term adverse effects of Lactobacillus live capsules represent an area for future study.
科研通智能强力驱动
Strongly Powered by AbleSci AI